'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand

Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to chief rival Eli Lilly—isn’t one to make changes for the sake of change.